Advertisement

Topics

European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis

07:30 EST 13 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
− Company on Track to Submit Marketing Authorization Application (MAA) and New Drug Application (NDA) at Year-End 2017 − Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announce...

Other Sources for this Article

Alnylam Pharmaceuticals, Inc.
(Investors and Media)
Christine Regan Lindenboom, 617-682-4340
or
(Investors)
Josh Brodsky, 617-551-8276

NEXT ARTICLE

More From BioPortfolio on "European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...